Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | 2026-04-02 15:13:11 | 6.88 | -0.02 | -0.29 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBYI | 0001401667 | PUMA BIOTECHNOLOGY, INC. | US74587V1070 | — | 770683487 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 10880 WILSHIRE BLVD. | LOS ANGELES | CA | 90024 | UNITED STATES | US | (424) 248-6500 | 10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024 | 10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024 | INNOVATIVE ACQUISITIONS CORP | — | — | — | 265 | http://pumabiotechnology.com | 145,200,000 | 50,408,023 | 50,876,487 | Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA. | 2026-04-02 18:22:28 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 145,200,000 | 10,800,000 | 8.0357 | 50,876,487 | 1,265,688 | 2.5512 |
| 2024 | 134,400,000 | -7,000,000 | -4.9505 | 49,610,799 | 1,403,637 | 2.9117 |
| 2023 | 141,400,000 | 29,500,000 | 26.3628 | 48,207,162 | 1,565,907 | 3.3573 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Alvin Wong | Chief Scientific Officer | 2024 | 413,683 | 0 | 275,433 | 0 | 374,263 | 1,338,769 |
| Jeff J. Ludwig | Chief Commercial Officer | 2024 | 608,499 | 60,850 | 172,146 | 194,355 | 20,320 | 1,228,288 |
| Alan H. Auerbach | Chief Executive Officer, President | 2024 | 904,207 | 0 | 1,055,548 | 938,612 | 16,210 | 3,969,931 |
| Maximo F. Nougues | Chief Financial Officer | 2024 | 538,719 | 123,905 | 275,433 | 172,067 | 19,462 | 1,404,978 |
| Jeff J. Ludwig | Chief Commercial Officer | 2023 | 596,568 | 77,554 | 294,007 | 85,309 | 33,134 | 1,381,848 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 179 |
| 2024 | 172 |
| 2023 | 185 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 228,371,000 | 230,468,000 | 235,637,000 |
| Cost Of Revenue | 58,157,000 | 64,404,000 | 62,682,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 62,068,000 | 54,935,000 | 50,382,000 |
| General And Administrative Expenses | 70,847,000 | 80,163,000 | 89,933,000 |
| Operating Expenses | 191,072,000 | 199,502,000 | 202,997,000 |
| Operating Income | 37,299,000 | 30,966,000 | 32,640,000 |
| Net Income | 31,111,000 | 30,278,000 | 21,591,000 |
| Earnings Per Share Basic | 0.62 | 0.62 | 0.46 |
| Earnings Per Share Diluted | 0.61 | 0.62 | 0.45 |
| Weighted Average Shares Outstanding Basic | 50,011,485 | 48,648,701 | 47,134,331 |
| Weighted Average Shares Outstanding Diluted | 50,653,283 | 49,100,433 | 47,550,852 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 29,635,000 | 69,219,000 | 84,585,000 |
| Marketable Securities Current | 67,893,000 | 31,746,000 | 11,354,000 |
| Accounts Receivable | 53,654,000 | 32,011,000 | 47,837,000 |
| Inventories | 5,515,000 | 8,724,000 | 7,080,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 256,000 | 91,000 | 912,000 |
| Total Assets Current | 162,686,000 | 147,658,000 | 156,185,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 187,000 | 515,000 | 855,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 53,616,000 | 65,675,000 | 74,343,000 |
| Total Assets | 216,302,000 | 213,333,000 | 230,528,000 |
| Accounts Payable | 5,056,000 | 5,509,000 | 6,889,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 22,523,000 | 45,329,000 | 33,997,000 |
| Other Liabilities Current | 142,000 | 36,898,000 | 52,721,000 |
| Total Liabilities Current | 81,253,000 | 96,111,000 | 99,382,000 |
| Long Term Debt | 22,675,000 | 68,003,000 | 102,000,000 |
| Other Liabilities Non Current | 0 | 121,000 | — |
| Total Liabilities Non Current | 4,709,000 | 25,097,000 | 77,704,000 |
| Total Liabilities | 85,962,000 | 121,208,000 | 177,086,000 |
| Common Stock | 5,000 | 5,000 | 5,000 |
| Retained Earnings | -1,283,775,000 | -1,314,886,000 | -1,345,164,000 |
| Accumulated Other Comprehensive Income | 36,000 | 6,000 | -4,000 |
| Total Shareholders Equity | 130,340,000 | 92,125,000 | 53,442,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 10,938,000 | 11,524,000 | 11,519,000 |
| Share Based Compensation Expense | 6,944,000 | 8,245,000 | 10,247,000 |
| Other Non Cash Income Expense | -4,000 | 0 | 0 |
| Change In Accounts Receivable | 21,281,000 | -16,345,000 | 8,368,000 |
| Change In Inventories | -3,209,000 | 1,644,000 | 2,554,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -453,000 | -1,380,000 | 449,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 41,802,000 | 38,918,000 | 27,009,000 |
| Purchases Of Marketable Securities | 108,141,000 | 76,230,000 | 23,813,000 |
| Sales Of Marketable Securities | 72,024,000 | 55,848,000 | 17,328,000 |
| Acquisition Of Property Plant And Equipment | 71,000 | 56,000 | 140,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -36,188,000 | -20,438,000 | -19,125,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 130,000 | 150,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -45,198,000 | -33,846,000 | 0 |
| Change In Cash | -39,584,000 | -15,366,000 | 7,884,000 |
| Cash At End Of Period | 29,635,000 | 69,219,000 | 84,585,000 |
| Income Taxes Paid | 1,524,000 | 1,218,000 | 737,000 |
| Interest Paid | 5,818,000 | 10,769,000 | 11,628,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.62 | 0.62 | 0.46 |
| Price To Earnings Ratio | 9.5968 | 4.9194 | 9.413 |
| Earnings Growth Rate | 0 | 34.7826 | — |
| Price Earnings To Growth Ratio | — | 0.1414 | — |
| Book Value Per Share | 2.6062 | 1.8937 | 1.1338 |
| Price To Book Ratio | 2.283 | 1.6106 | 3.8189 |
| Ebitda | 50,195,000 | 55,472,000 | 47,177,000 |
| Enterprise Value | 313,131,335.75 | 192,491,538.05 | 255,503,653.23 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.3468 | 1.2302 | 2.5448 |
| Capital Expenditures | 10,610,000 | 11,184,000 | 11,228,000 |
| Free Cash Flow | 31,192,000 | 27,734,000 | 15,781,000 |
| Return On Equity | 0.2387 | 0.3287 | 0.404 |
| One Year Beta | 0.5962 | 1.1227 | 1.3011 |
| Three Year Beta | 0.8761 | 1.1867 | 1.1096 |
| Five Year Beta | 0.9758 | 1.1379 | 1.1759 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| NOUGUES MAXIMO F | Chief Financial Officer | 2026-02-18 | 46,739 | A | 240,023 |
| NOUGUES MAXIMO F | Chief Financial Officer | 2026-02-18 | 66,541 | A | 66,541 |
| HUNT DOUGLAS M | — | 2026-02-18 | 49,394 | A | 205,301 |
| HUNT DOUGLAS M | — | 2026-02-18 | 70,321 | A | 70,321 |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | 2026-02-18 | 159,778 | A | 7,305,729 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 4,724,074 | 793,962 | 5.95 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 946 | 159 | 5.9497 |
| Sunbelt Securities, Inc. | 2025-12-31 | 178 | 30 | 5.9333 |
| Invesco Ltd. | 2025-12-31 | 644,391 | 108,301 | 5.95 |
| Empowered Funds, LLC | 2025-12-31 | 1,107,801 | 186,185 | 5.95 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 19,641 | 127,273.68 | 0.0092 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 60,180 | 389,966.4 | 0.0146 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GSXPX | 125,300 | 811,944 | 0.0874 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GTTUX | 125,300 | 811,944 | 0.0874 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Investor Shares | GTTTX | 125,300 | 811,944 | 0.0874 |